Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 2/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427078 | 1.00 | KMO (0.55) | KMOEGFRIRAK4NOTUMERCC1 | |
| SCHEMBL31731004 | 0.87 | KMO (0.48) | KMOEGFRIRAK4NOTUMERCC1 | |
| SCHEMBL11794 | 0.84 | EGFR (0.46) | KMOEGFRPDE1CCYP11B2CYP1A2 | |
| SCHEMBL6181444 | 0.79 | KMO (0.59) | KMOIRAK4NOTUMFGFR1FGFR4 | |
| SCHEMBL30381343 | 0.79 | KMO (0.59) | KMOIRAK4NOTUMFGFR1FGFR4 | |
| SCHEMBL17673818 | 0.78 | KMO (0.66) | KMOEGFRIRAK4FGFR1FGFR4 | |
| SCHEMBL13106103 | 0.78 | PTK2 (0.54) | MPOCYP1A2GRM4VNN1 | |
| SCHEMBL27261035 | 0.78 | EGFR (0.43) | KMOEGFRIRAK4ESRRGHTR2A | |
| SCHEMBL29901474 | 0.78 | KMO (0.57) | KMONOTUMERCC1ERCC4ESRRG | |
| SCHEMBL425168 | 0.78 | KMO (0.57) | KMONOTUMERCC1ERCC4ESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258318-B2 | Synthesis method for 1-methyl-1H-indazole-6-carboxylic acid | ACCELA CHEMBIO CO., LTD. (CN) | 2025-03-25 | — | — | US | claimed |
| US-20220235010-A1 | SYNTHESIS METHOD FOR 1-METHYL-1H-INDAZOLE-6-CARBOXYLIC ACID | ACCELA CHEMBIO CO., LTD. (CN) | 2022-07-28 | — | — | US | claimed |
| WO-2020253533-A1 | SYNTHESIS METHOD FOR 1-METHYL-1H-INDAZOLE-6-CARBOXYLIC ACID | 韶远科技（上海)有限公司 | 2020-12-24 | — | — | WO | claimed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-12570607-B2 | Compound as cyclin-dependent kinase 9 inhibitor and use thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| EP-4387963-B1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | REDX PHARMA LTD (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| WO-2007084451-A1 | HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| CN-1863532-A | Azaspiroalkane derivatives as metalloproteinase inhibitors | INCYTE COPORATION (US) | 2006-11-15 | — | — | CN | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION | 2004-12-23 | — | — | US | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | KMO 64/4885EGFR 158/4885IRAK4 365/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | KMO 1686/4885EGFR 1670/4885IRAK4 3103/4885 |
| US-12570607-B2 | Compound as cyclin-dependent kinase 9 inhibitor and use thereof | CDK9, CDK4, CDKL4 | KMO 2243/4885EGFR 859/4885IRAK4 1385/4885 |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP9, DPP7, DPP4 | KMO 2575/4885EGFR 1496/4885IRAK4 1666/4885 |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | KMO 1734/4885EGFR 1457/4885IRAK4 359/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | KMO 687/4885EGFR 3359/4885IRAK4 120/4885 |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | MMP9, MMP25, HDAC5 | KMO 38/4885EGFR 1726/4885IRAK4 659/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | KMO 1040/4885EGFR 1378/4885IRAK4 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.